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For the full text of this licence, please go to: http://creativecommons.org/licenses/by-nc-nd/2.5/ Introduction 1 2 Over the past three decades there has been significant interest in the therapeutic potential of fish 3 oils for various inflammatory conditions such as rheumatoid arthritis, inflammatory bowel diseases, and 4 asthma. Fish oil, rich in omega-3 (n-3) polyunsaturated fatty acids (PUFA), such as eicosapentaenoic acid 5 (EPA) and docosahexaenoic acid (DHA), appear to have additional antiphlogistic properties primarily 6 through their effects on the neutrophil and macrophage (M ) component of the inflammatory response 1-7 . 7 Eicosapentaenoic acid can compete with arachidonic acid (AA), as a substrate for 8 cyclooxygenase (COX)-2 and 5-lipoxyeganse (5-LO) enzymes and be converted to less inflammatory 9 eicosanoids 6, 8 . At present the mechanism(s) underpinning the anti-inflammatory effects of DHA are 10 unclear, but may be related to altered gene transcription and translation via direct or indirect actions on 11 intracellular signaling pathways 9-11 . In addition, n-3 PUFA-derived mediators such as lipoxin, 12 docosatrienes resolvins and neuroprotectins may also have anti-inflammatory, pro-resolving and 13 protective properties 12 . 14 The observational evidence on fish oil effects has been relatively consistent in demonstrating 15 protection against asthma and/or allergy in relation to a high intake, and ecological and other cross-16 sectional data support the hypothesis that n-6 PUFA may increase and n-3 PUFA may decrease asthma 17 risk 13 . While the clinical data on the effect of fish oil supplementation in asthma has been equivocal 18 14 supplementing the diet with fish oil in individuals with exercise-induced asthma (EIA) has yielded 19 promising results 15, 16 . Our laboratory has shown that 3 weeks of fish oil supplementation reduced the 20 severity of EIA, airway inflammation and bronchodilator use, and improved asthma symptoms scores in 21 elite athletes 15 and asthmatic individuals 16 .
22
The majority of studies investigating the effects of n-3 PUFA on asthma/EIA have either 23 employed fish oils rich in EPA or oils which contain a heterogeneous blend of EPA and DHA. Only a 24 few studies have examined the effects of supplementing asthmatic patients with pure EPA and/or DHA, 25 with conflicting results 14 . Data is therefore insufficient to make recommendations for intake of specific 26 n-3 PUFA in asthma, e.g. EPA versus DHA versus EPA + DHA combined 17 . Although many studies have investigated the effects of EPA and DHA on macrophage function in animal models and cell lines, 1 there is little evidence about the effects of these lipids on primary human macrophages obtained from 2 asthmatic patients.
3 Therefore, the main aim of this study was to compare the individual effects of EPA and DHA, 4 and a variety of heterogeneous blends of EPA and DHA, on eicosanoid and cytokine generation from 5 LPS-stimulated human asthmatic alveolar macrophages (AM ). In addition, the effects of EPA and DHA 6 on cytokine mRNA expression were investigated in the LPS-stimulated AM .
8
Methods 9 10
Twenty non-smoking adults with asthma were recruited to this study. Asthma was diagnosed by a 11 history of recurrent wheezing and chest tightness and a previous physician diagnosis. All subjects had 12 clinically treated mild-to-moderate persistent asthma, with an FEV 1 greater than 70% of predicted 18 .
13
Inhaled corticosteroids, 5-lipoxygenase inhibitors and leukotriene receptor antagonists were withheld for 14 4 weeks prior to fiberoptic bronchoscopy. Subjects were also excluded if they had a history of taking n-3 15 PUFA supplements or consumed more than one fish meal per week. A group of nonasthmatic (control) 16 subjects was not included in the present study as it has been shown that fish oil supplementation does not 17 alter pulmonary function or inflammatory mediator generation in this population 15 . The local Institutional
18
Research Ethics Committee approved the study protocol. 19 20 Fiberoptic Bronchoscopy.
21
Fiberoptic bronchoscopy was used to obtain BALF from each subject. Using local anesthesia with 22 lidocaine (2% wt/vol) to the upper airways and larynx, a fiberoptic bronchoscope was passed through the 23 nasal passages into the trachea. The bronchoscope was wedged in the right middle lobe and 4 × 60-ml 24 aliquots of prewarmed sterile 0.9% NaCl solution were instilled. This solution was aspirated through the 25 bronchoscope, collected in prechilled glass bottles, and stored on ice and processed within 30 min.
Separation of AM from BALF.
1 AM cells were separated from BALF using previously described methods, with slight 2 modifications 19 . Briefly, the BALF was filtered through a single layer of coarse sterile gauze to remove 3 mucus clumps and then centrifuged at 1,000 g for 10 min at 4° C to obtain a cell pellet. The cell pellet was 4 washed once in 50 ml of Ca 2+ / Mg 2+ free Hanks' balanced salt solution (HBSS). The cells were counted on 5 a hemocytometer slide using a Kimura counterstain and viability assessed by the trypan blue exclusion 6 test. Cytospins were performed, using 10 4 cells per slide, and stained with May-Grunwald-Giemsa in 7 order to obtain differential cell counts ( Table 1 ). The remaining cells were resuspended at a concentration 8 of 2 × 10 6 AM per milliliter in RPMI 1640 medium supplemented with 10% (vol/vol) fetal calf serum, 9 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. 2 × 10 6 AM /well were plated onto 10 6-well plates and allowed to adhere for 90 min in a humidified incubator in 95% air, 5% CO 2 (vol/vol), at 11 37° C. Nonadherent cells were removed by washing three times with RPMI 1640 medium, leaving the 
23
All fatty acids were dissolved in distilled H 2 O, aliquoted, and stored under an N 2 stream, and 24 stored at -80oC for no longer than 1 week prior to use. EPAX 4510 TG is a triglyceridic oil containing 25 approximately 45% EPA and 10% DHA, with saturated fatty acids and monounsaturated fatty acids comprising 9-12% and 20-24% respectively. EPAX 1050 TG is triglyceridic oil containing approximately 1 10% EPA and 50% DHA, with saturated fatty acids and monounsaturated fatty acids comprising 2-10% 2 and 5-15% respectively. The fluid recovered, total cell count and percent differential airway cell counts recovered from 2 bronchial samples are presented in Table 1 . The unstimulated AM cells did not demonstrate any 3 significant differences (p>0.05) in LTB 4 , PGD 2 , TNF-or IL-1 production among the high dose (120 4 µM) treatment groups (Figure 1, panel A-D) . DMEM pretreated controls demonstrated a significant 5 increase (p<0.05) in LTB 4 , PGD 2 , TNF-and IL-1 production in response to LPS stimulation (Figure 1 
16
Since differences in LPS-stimulated eicosanoid and cytokine production were observed at the 17 high dose (120 µM) we also examined whether these differences would be noticeable at a lower dose of 18 n-3 PUFA (25µM). Figure 2 (panel A-B ) presents the effects of LPS-stimulated LTB 4 and TNF-19 production in AM cells pretreated with 25 µM pure EPA, pure DHA, EPAX4510, EPAX1050 and 20 Lipovenos R . The anti-inflammatory response at the 25µM dose followed a similar pattern as the 120µM 21 n-3 PUFA dose, but had significantly (p<0.05) less of an inhibitory effect on LPS-stimulated AM LTB 4 22 and TNF-production ( Figure 2, panel A-B) . A comparable effect was seen for LPS-stimulated PGD 2 23 and IL-1 production (data not shown).
24
The effect of the high dose (120µM) and low dose (25µM) n-3PUFA was also examined at the 1 panel A-B). The inhibitory effect of 120 µM pure-EPA on LPS-stimulated TNF-and IL-1 mRNA 2 expression was significantly greater (p < 0.05) than that of 120 µM pure-DHA, EPAX4510, EPAX1050 3 and Lipovenos R (Figure 3, panel A) . Interestingly, the effect of 25 µM n-3 PUFA on LPS-stimulated 4 TNF-and IL-1 mRNA expression followed a similar pattern to the 120µM pretreated cells (Figure 3 This study has demonstrated for the first time that pure EPA media reduced TNF-and IL-1 9 mRNA expression and the production of LTB 4 , PGD 2 and TNF-and IL-1 from LPS-stimulated primary 10 AM cells obtained from asthmatic patients to a much greater extent than pure DHA. Interestingly, the 11 EPA-rich media (EPAX 4510) significantly reduced cytokine mRNA expression and generation of 12 eicosanoids and cytokines from LPS-stimulated AM cells to a much greater degree than both the pure 13 DHA and the DHA-rich media (EPAX 1050), suggesting that the greater the EPA content of an n-3 14 PUFA formulation the greater the eicosanoid and cytokine reduction. Whilst these experiments were 15 conducted at a comparatively high n-3 PUFA dose (120 µM) we also observed a similar pattern of LPS-16 stimulated AM cytokine and eicosanoid production and cytokine mRNA expression inhibition on a 17 much lower n-3 PUFA concentration (25 µM). Although our findings agree with a number of human 18 studies that have shown that fish oil suppressed cytokine production in LPS-stimulated mononuclear cells 19 4, 23, 24 , other studies have not shown this response [25] [26] [27] . 20 While there are a few studies that have assessed the efficacy of n-3 PUFA on cytokine production 21 using human THP-1 monocytes 10, 28, 29 and murine macrophages 2, 7, 20 , our study is the first to assess the 22 efficacy of a variety of n-3 PUFA blends on eicosanoid and cytokine production from AM obtained 23 directly from human asthmatic patients. Our data, for the most part, agree and expand the few studies human THP-1 monocytes, which although may behave like native monocyte -derived macrophages in comparison to other human myeloid cell lines, may express a different physiologic response compared to 1 primary human AM when exposed to a n-3 PUFA.
2
The present study has demonstrated that n-3 PUFA inhibits LTB 4 and PGD 2 from LPS-stimulated 3 human AM . Our results concur with several studies in which dietary supplementation with EPA and 4 DHA reduced inflammatory eicosanoids such as products generated via the 5-lipoxygenase pathway of 5 neutrophils and monocytes and an attenuation of LTB 4 -mediated chemotaxis 6 , and decreased PGE 2 6 production in LPS-stimulated murine RAW 264.7 cells pretreated with Omegaven® compared to control 7 cells 3 .
8
In the present study we evaluated the release of particular proinflammatory eicosanoids, derived 9 from both the cyclooxygenase (COX) and 5-lipoxygenase (5-LO) pathway such as PGD 2 and LTB 4 , and a 10 few key proinflammatory cytokines (IL-1 and TNF-) that have been directly implicated in the 11 pathogenesis of asthma. LTB 4 is a potent neutrophil chemoattractant factor in the airways 32 , while PGD 2 12 is a potent bronchoconstrictor and is thought to play a role in pathogenesis of asthma, in particular during 13 the early asthmatic response to allergen 33 . IL-1 induces airway neutrophilia, and increased expression of 
19
Our findings indicate that that EPA is a more potent inhibitor than DHA of LPS-stimulated suggest potentially novel therapeutic treatment strategies for asthma 12 . In addition, since we have 14 previously shown that the amount of LTB 5 generated from activated PMNLs was markedly 15 increased following fish oil supplementation in asthmatic patients 16 , further studies should 16 investigate the effect of fish oil on EPA and DHA-derived (anti-inflammatory) mediators 17 generated from human asthmatic AM 46 . 18 In conclusion the present study has shown for the first time that EPA is a more potent inhibitor 19 than DHA of inflammatory responses in human asthmatic AM cells. In addition, the present study has 20 shown that the greater the EPA content of a fish oil formulation the greater the inhibition of the 21 inflammatory response. Elucidating the mechanism of this modulation could help us to understand how 22 dietary n-3 PUFA achieves their specific effects on airway inflammation in asthmatic individuals. The The authors would like to thank the participating asthmatic adults for volunteering to this study. 
